Midazolam + Palonosetron

This combination therapy consists of midazolam, a short-acting benzodiazepine, and palonosetron, a selective 5-HT3 receptor antagonist. The combination is primarily used for preventing postoperative nausea and vomiting (PONV), particularly in high-risk patients. Midazolam possesses anxiolytic, amnestic, and anesthetic properties, while palonosetron works by selectively antagonizing 5-HT3 receptors both centrally (in the medullary chemoreceptor zone) and peripherally (in the GI tract). When combined, these medications appear to have a synergistic effect in preventing PONV, especially during the early postoperative period (0-2 hours). Several clinical studies have compared the efficacy of this combination therapy versus palonosetron monotherapy: * One study found that the combination of midazolam with palonosetron significantly decreased the incidence (38.2% vs 5.9%) and severity of postoperative nausea at 2 hours after surgery compared to midazolam with ramosetron. * Another study concluded that the combination of palonosetron and midazolam had superior antiemetic efficacy compared to a single injection of palonosetron in female patients undergoing laparoscopic cholecystectomy, particularly in reducing postoperative nausea and antiemetic administration in the initial 2 hours after surgery. Administration is typically intravenous after induction of anesthesia. Various dosages have been studied, including midazolam 0.05 mg/kg combined with palonosetron 0.075 mg. In some studies, the combination was administered through patient-controlled analgesia (PCA). This combination therapy has been primarily studied in female patients, non-smokers, patients undergoing procedures known to have high PONV risk (like laparoscopic cholecystectomy), and patients with ASA physical status I or II. When using this combination, clinicians should be aware that midazolam can increase the risk of sedation and CNS depression when combined with palonosetron. The short half-life of midazolam (1.5-2.5 hours) may explain why the combination shows particular efficacy in the early postoperative period. This combination represents an important option for preventing PONV, especially in high-risk patients where monotherapy may not provide adequate protection.